Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis.

Next Previous
X
Search
Trial Profile

Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Telmisartan (Primary)
  • Indications Secondary hypertension
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 01 Feb 2012 Results published in Clinical and Experimental Hypertension (CEH).
    • 25 Jan 2010 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 25 Jan 2010 Actual initiation date (Jan 2010) added as reported by University Hospital Medical Information Network - Japan record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top